Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · September 08, 2022

ESC 2022: DELIVER Demonstrates Benefits of Dapagliflozin in Heart Failure Regardless of Left Ventricular Ejection Fraction

Findings confirm the utility of SGLT2 inhibitors as foundational therapy for heart failure

PracticeUpdate Editorial Team


Further Reading